Indaptus partners with BeiGene to test Decoy20 + tislelizumab combo in solid tumors

Indaptus Therapeutics, Inc.

Clinical supply agreement with BeiGene Switzerland GmbH for anti-PD-1 antibody tislelizumab.
Indaptus funds all study costs except BeiGene's product; BeiGene supplies tislelizumab.
Plans to seek FDA approval and begin combination study in 2025 for advanced solid tumors.
Decoy20 is Indaptus' novel immune-response-inducing candidate for cancer therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.